Using 68Ga-PSMA-11 PET/CT to Diagnose and Monitor Cancer
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
This study is testing if a special type of scan can help doctors find and keep track of cancer in patients with different kinds of the disease.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT04831541 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic cancer lesions, as well as monitoring recurrence in patients with various types of cancer. Participants will undergo PET/CT scans to assess tumor uptake, with key metrics such as sensitivity, specificity, and accuracy being calculated. The study aims to provide insights into the utility of this imaging technique for cancer management.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected or newly diagnosed malignant tumors who are scheduled for a 68Ga-PSMA-11 PET/CT scan.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of cancer diagnosis and monitoring, leading to better patient outcomes.
How similar studies have performed: Other studies have shown promising results with similar imaging techniques, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (i) adult population (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled 68Ga-PSMA-11 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: (i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.